


Original Article

IJTID

(INDONESIAN JOURNAL OF TROPICAL AND INFECTIOUS DISEASE)

Scientific Journal of Tropical and Infectious Disease



Fungemia in Tertiary Hospitals; An Overview Fungal Profile, Antifungal Resistance, and Antifungal Therapy

Syafira Putri Monita¹, Pepy Dwi Endraswari^{2,4*} , Bramantono^{3,4} , Tri Pudy Asmarawati^{3,4,5} , Sarah Amjad Abdel-Raouf Khanfar⁶

¹Medical Program Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

²Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

³Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

⁴Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

⁵Universitas Airlangga Hospital, Surabaya, Indonesia

⁶Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan



ARTICLE INFO

Received: December 11, 2024

Accepted: January 3, 2025

Published: April 30, 2025

Available online: April 30, 2025

*) Corresponding author:

E-mail: pepy.dr@fk.unair.ac.id

Keywords:

Fungemia
Infection
Antifungal
Resistance
Therapy



This is an open access article under the CC BY-NC-SA license

(<https://creativecommons.org/licenses/by-nc-sa/4.0/>)

Abstract

Fungemia is a bloodstream infection caused by fungal pathogen and commonly occurs in hospitalized patients with certain risk factors. Indonesia itself is a tropical country with middle income that makes the incidence rate of fungemia tend to be higher, namely 10/10,000 people. A recent study about candidemia conducted in Dr. Soetomo General Academic Hospital stated that the most common species that caused candidemia is *Candida albicans* (33.96%) and the blood sample mostly collected from patients from high care unit and patient with diabetes. We conducted this study to provide a new overview of data on the profile of the causes of fungal infections, patterns of fungal resistance to antifungals, and antifungal therapy in patients with fungemia in hospitalized patients at Dr. Soetomo General Academic Hospital, Surabaya, for the period of January - December 2023. This research is a descriptive study using the patient's medical records. Variables observed in this study include; gender, age, care unit, risk factor, species distribution, resistance pattern, type of antifungal therapy, and duration of antifungal therapy. Mostly the blood cultures are collected from female patients aged 0-9 years old. This study also found that most blood cultures are collected from patients in intensive care unit with use of CVC. Most of the patients did not receive antifungal therapy. The most frequent found species is *Candida parapsilosis* with highest resistance rate found in Amphotericin-B. The most common antifungal that is used is Fluconazole which is mostly given within the range of 8-14 days.

Cite this as: Monita, S.P., Endraswari, D.P., Bramantono, Asmarawati, T.P., and Khanfar, S.A.A. (2025). Fungemia in Tertiary Hospitals; An Overview Fungal Profile, Antifungal Resistance, and Antifungal Therapy. *Indonesian Journal of Tropical and Infectious Disease*, 13(1) : 31–38. <https://doi.org/10.20473/ijt.v13i1.66500>

INTRODUCTION

Fungemia is a bloodstream infection caused by fungal pathogen and commonly occurs in hospitalized patients with certain risk factor^{1,2}. Fungal pathogen can be divided into two categories; opportunistic and endemic agent which is influenced by geographic factors.² Fungemia is one of the problems in intensive care units especially in developing and middle income countries.¹ In Indonesia, the current data of incidence rate of candidemia is 10/10,000 with 30% mortality rate.³ According to previous study about candidemia in Dr. Soetomo General Academic Hospital, the most common species that caused candidemia is *Candida albicans* (33,96%) and mostly the blood cultures are collected from intensive care units with the most common risk factors being CVC use and patients with diabetes mellitus.⁴

Until now, the gold standard method to diagnose fungemia is blood culture with macroscopic and microscopic examination for antifungal susceptibility test⁵. Based on other study, increased number of mortality rate in fungemia patient with high risk factor is caused by fungal resistance; furthermore, it is important to discuss about resistance rate of fungal agents.^{6,7}

Research about fungemia has rarely been done in developing countries, especially in Indonesia, although the incidence rate tends to be higher in developing countries. Dr. Soetomo General Academic Hospital itself is a tertiary hospital with many inpatient cases that require intensive care; however, until now there has not been found any study about species distribution of fungemia patients, patterns of fungal resistance, and therapy of fungemia patients. Therefore it is hoped that this study will provide the latest information to improve the

management of patients' treatment and reference for study related to fungal bloodstream infection in the future.

MATERIALS AND METHODS

Population and Sample

The data used in this research were secondary data from medical records of inpatients with fungemia in Dr. Soetomo General Academic Hospital from January 2023 until December 2023. The sample used in this research is all medical records that contain patient's demographic data, inpatient unit, risk factor, antifungal sensitivity test results, antifungal therapy and the duration of antifungal therapy use. The total number of fungemia inpatients is 146 and the number of patients that meet all the criteria is 125 patients.

Methods

This research design is an observational study with retrospective approach to observe profile of fungemia inpatients in RSUD Dr. Soetomo within January – December 2023.

RESULTS AND DISCUSSION

The research results showed that the majority of fungemia inpatients is within the children age group between 0 – 9 years old, especially in <0 years old. This finding is similar to previous study about candidemia in Dr. Soetomo General Academic Hospital which stated that the highest incidence rate of candidemia occurred in the age group <0 years old.⁴ In patients in the age group age <1 years old the immune system has not fully developed which causes them to be more susceptible to fungal pathogen.⁶ A common immunological that effectively kills fungal pathogen is Th1 or Th17 immune response which only develops at early childhood stage > 1 year old.⁸ As

shown in Table 1, there are not significant differences between number of male and female fungemia inpatients, which is relevant to previous study that stated gender is not the main risk factor in fungemia.^{4,1} The majority of the blood cultures are isolated from the patients in ICU followed by patients in HCU. This study has similar results to other study that fungemia is more common among ICU patients due to many invasive procedures that tend to be occurred in ICU.^{9,10} Fungemia tends to be an opportunistic infection which mainly infects individuals with risk factors.¹¹ In this study, most of the patients had several risk factors. Table 1 shows that in this research the most common risk factor is CVC usage. This result is similar to previous study that CVC usage is a common risk factor in fungemia patients due to catheters used are contaminated with fungal pathogens.^{4,12}

Table 1. Characteristics of fungemia inpatients in Dr. Soetomo Surabaya General Academic Hospital, January 2023 – December 2023

Predictor	Amount	Percentage
Age		
0 – 9 years old	66	52.80
10 – 19 years old	9	7.20
20 – 29 years old	3	2.40
30 – 39 years old	9	7.20
40 – 49 years old	9	7.20
50 – 59 years old	15	12.00
>59 years old	14	11.20
Gender		
Male	62	49.60
Female	63	50.40
Medical Units		
Intensive care unit	33	26.40
High care unit	30	24.00
Pediatric wards	15	12.00
Medical wards	13	10.40
Neonatal intensive care unit	13	10.40
Surgery wards	9	7.20
Neonatal high care unit	6	4.80
Isolation wards	4	3.20
Pediatric intensive care unit	1	0.80
Pediatric high care unit	1	0.80

Risk Factor	Frequency n(%), n=125
CVC	44.00%
TPN	40.00%
Surgery	38.40%
Use of broad spectrum antibiotics > 14 days	24.80%
Preterm infants	21.60%
Patient with diabetes mellitus	13.60%
CKD	9.60%
Malignancy	7.20%
Immunocompromised	4.80%

Based on Table 2, the blood culture results from fungemia inpatient in 2023 found 125 fungal isolates with 15 species. The species that is commonly found in the blood culture is *Candida parapsilosis* (40.0%) followed by *Candida tropicalis* (20.00%) and *Candida glabrata* (12.00%). The results about species distribution on this study is not common, because several other studies had the result that the common cause of fungemia is *Candida albicans* which is believed to be caused by the azole antifungal used was not very common at that time.^{13,4} However, currently, use of azole antifungals as therapy is very common which leads to decreased incidence of *Candida albicans* fungemia.¹⁴ However this has caused an increasing incident of *Candida non-albicans* caused by *Candida non-albicans* resistance to azole antifungals.¹⁴ A study having a similar result to this study was conducted in Japan that showed *Candida parapsilosis* being the most common species found in fungemia patients.¹⁵ This is believed caused by use of echinocandins as antifungal treatment which is not relevant with this study because only two patients received echinocandin as antifungal therapy.¹⁵

Improper use of antifungal treatment could lead to fungal resistance which has many predisposing factors that can lead to antifungal resistance.¹⁶ Antifungal resistance mechanism in *Candida* species includes gene mutation, efflux pump overexpression, and biofilm formation.¹⁷ Another study stated the incidence rates of fungemia caused by *Candida parapsilosis* have increased over the last two decades due to nosocomial transmission from prolonged use of medical devices such as Central Venous Catheter (CVC) and Top Parenteral Nutrition (TPN).^{14,18} Another study stated that *Candida parapsilosis* has ability to form biofilm on Central Venous Catheter or other prosthetic material and ability to grow in Top Parenteral Nutrition solutions, by which it can be concluded that *Candida parapsilosis* blood stream infections (BSI) are related to the exogenous route of fungal infection, which is relevant to this study.¹⁹ In this study, *Candida tropicalis* is the most common fungal pathogen found in the patient's blood culture after *Candida parapsilosis*. Several studies conducted in tropical countries concluded that fungemia caused by *Candida tropicalis* commonly occurred in tropical countries such as Latin America and Asia.^{20,21} Several studies stated that the decreased incidence of fungemia caused by *Candida albicans* is believed due to increased use of azole antifungals each year while the resistance rate of azole in *Candida albicans* species tends to be lower, which causes the change of incidence rate between fungemia caused by *Candida albicans* and *Candida non-albicans* each year.^{22,4}

Table 2. Fungal species distribution from fungemia inpatients in Dr. Soetomo Surabaya General Hospital, January 2023 – December 2023

Species	Frequency	Percentage
<i>Candida non-albicans</i>		

<i>Candida parapsilosis</i>	51	40.80%
<i>Candida tropicalis</i>	26	20.80%
<i>Candida glabrata</i>	15	12.00%
<i>Candida haemulonii</i> var <i>vulnera</i>	5	4.00%
<i>Candida haemulonii</i>	4	3.20%
<i>Candida duobushaemulonii</i>	3	2.40%
<i>Candida dubliniensis</i>	1	0.80%
<i>Candida guilliermondii</i>	1	0.80%
<i>Candida krusei</i>	1	0.80%
<i>Candida lusitanae</i>	1	0.80%
<i>Candida rugosa</i>	1	0.80%
<i>Candida utilis</i>	1	0.80%
<i>Candida albicans</i>	11	8.80%
<i>Cryptococcus neoformans</i>	2	1.60%
<i>Kodamaea ohmeri</i>	2	1.60%

Antifungal that is used for therapy is one of the main factors for successful therapy in fungemia patients; therefore, the patients that show symptoms of fungemia have to do a blood culture test to check whether there is an fungal pathogen and its sensitivity pattern.¹ As shown in Table 3, there are found several isolates that are resistant to Amphotericin-B, Micafungin, and Caspofungin which tends to be different from other study. Other study stated that fungal pathogens are commonly susceptible to echinocandin and polyene.²³ However, there is a study that has similar results by which Amphotericin-B has a high resistance rate especially in *Candida non-albicans* isolate.²⁴ Fungal resistance to Amphotericin-B is associated with ERG-3 gene mutation while fungal resistance to Micafungin and Caspofungin is linked to mutation in units FKS1 and FKS2.^{25,26} Furthermore, in this study there are found several isolates from *Candida non-albicans* that are resistant to azole antifungals such as Fluconazole and Voriconazole. Several studies stated that resistance to azole antifungals are commonly occurred in *Candida non-*

albicans isolate especially in *Candida glabrata* which is linked with mutation in ERG-11 gene.^{27,23,28} Therefore, in this research it can be concluded that the most frequent found species is *Candida parapsilosis* with highest resistance rate found in Amphotericin-B. In several studies it is stated that there is found a significant degree of resistance rate of Amphotericin-B in *Candida parapsilosis* isolates.²⁹

Table 3. Resistance rate to antifungal of fungemia inpatients in Dr. Soetomo Surabaya General Hospital, January 2023 – December 2023

Species (Frequency)	Antifungal (Isolates)	Resistance (%)
<i>Candida albicans</i> (11)	Amphotericin-B (11)	9.09
	Micafungin (11)	9.09
	Fluconazole (88)	1.14
<i>Candida non-albicans</i> (110)	Voriconazole (102)	1.96
	Caspofungin (83)	4.82
	Amphotericin-B (105)	11.3
	Flucytosin (107)	0.93
	Micafungin (93)	1.08

As shown in Table 4, 52% patients having fungal pathogen from the blood culture test were not treated with antifungal treatment, which is relevant to the Infectious Disease Society of America (IDSA) guideline that stated antifungal treatment should be given to patients tested positive for fungal pathogen in blood culture and having symptoms of infections such as fever.³⁰ This study further shows that the outcomes of the patient given antifungal treatment is that 56% of the patients are discharged. However, a successful therapy involves many other factors such as risk factors and duration of the treatment.⁹ Based on Table 5, most of the patients that met the

criteria to receive antifungal treatment were given fluconazole, which is similar to a study conducted in Tehran.¹³ It occurs because Fluconazole is a broadspectrum antifungal and has several mechanisms of action such as overexpression of ERG-11 gene which is caused by the existence of Upc2 transcription factor and mutation of ERG-3 gene which cause thinning of the ergosterol wall.^{31,28} In this study, it was also found that antifungal treatment is mostly given within the range of 8-14 days; however, several patients were discharges and there was not found a continuation of antifungal treatment.

Table 4. Antifungal therapy of fungemia inpatients in Dr. Soetomo Surabaya General Academic Hospital, January 2023 – December 2023

	Frequency	Percentage
Treated with antifungal	60	48%
Not treated with antifungal	65	52%

Table 5. Antifungal therapy and duration of antifungal therapy given to fungemia inpatients in Dr. Soetomo Surabaya General Academic Hospital, January 2023 – December 2023

	Frequency (%) n=60
Antifungal	
Fluconazole	58 (96.67%)
Micafungin	2 (3.33%)
Duration	
1-7 days	58 (96.67%)
8-14 days	2 (3.33%)
15-21 days	58 (96.67%)
22-28 days	2 (3.33%)
29-35 days	58 (96.67%)

STRENGTH AND LIMITATION

The strength of this study is there are not many studies about fungemia, especially in Indonesia, even though the incidence rates are high among ICU patients.

However, the limitations of this study were due to incomplete medical records especially on the duration of antifungal treatment, which caused inadequate data of duration of antifungal therapy.

CONCLUSIONS

This study shed light on the species distribution, patterns of antifungal resistance, and therapy of fungemia patients in Dr. Soetomo General Academic Hospital, Indonesia. The most frequent found species is *Candida parapsilosis* with highest resistance rate found in Amphotericin-B. Most of the patients did not receive antifungal therapy. Early detection and proper treatment is important for successful treatment of fungemia patients. This study highlights the importance of giving proper treatment to increase successful rate of treatment and decrease the risk of antifungal resistance of fungemia patients.

ACKNOWLEDGMENT

This study was supported by the Faculty of Medicine Airlangga University, Surabaya and Dr. Soetomo Academic Hospital, Surabaya.

ETHICAL CLEARANCE

The use of medical records for the data in this research is approved by the ethics committee of Dr. Soetomo Surabaya General Academic Hospital (1691/LOE/301.4.2/VI/2024).

FUNDING

This study did not receive any funding.

CONFLICT OF INTEREST

All of the authors declare that they have no conflict of interest.

AUTHOR CONTRIBUTION

Every author in this study equally contributed from the design to the implementation of the research, result analysis, and writing the manuscript.

REFERENCES

1. Alejandra L, Cuervo-maldonado SI, Enciso-Olivera JL, et al. Fungemia in Hospitalized Adult Patients with Hematological Malignancies: Epidemiology and Risk Factors. *J Fungi (Basel)*. 2023;9(4):400.
2. Gaona-Flores VA, Campos-Navarro L, Cervantes-Tovar R, et al. The epidemiology of fungemia in an infectious diseases hospital in Mexico city: A 10-year retrospective review. *Med Mycol* 2016; 54: 600–4.
3. Fatril AE, Robiatul Adawiyah, Retno Wahyuningsih. Pola Kepekaan *Candida krusei* Isolat Jakarta terhadap Flukonazol. *J Indones Med Assoc* 2020; 70: 110–14.
4. Ayu Pratiwi C, Surya Airlangga P, Dwi Endraswari P. An Overview of Candidemia Patients in Tertiary Hospital, Surabaya, Indonesia. *Int J Res Publ* 2022; 111: 78–85.
5. Engelkirk P. *Burton's Microbiology for the Health Sciences 11th edn*. 2020.
6. Adam L, O'Connor C, Garcia AC. Evaluating the Impact of Diabetes Self-Management Education Methods on Knowledge, Attitudes

- and Behaviours of Adult Patients With Type 2 Diabetes Mellitus. *Can J Diabetes* 2018; 42: 470-7.e2.
7. Fisher MC, Alastruey-Izquierdo A, Berman J, et al. Tackling the emerging threat of antifungal resistance to human health. *Nat Rev Microbiol* 2022; 20: 557–71.
 8. Spellberg B. Vaccines for invasive fungal infections. *F1000 Med Rep* 2011; 3: 1–8.
 9. Sprute R, Nacov JA, Neofytos D, et al. Antifungal prophylaxis and pre-emptive therapy: When and how? *Mol Aspects Med* 2023; 92: 101190.
 10. Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. *Int J Antimicrob Agents* 2008; 32: 87–91.
 11. Li Y, Du M, Chen LA., et al. Nosocomial Bloodstream Infection Due to *Candida* spp. in China: Species Distribution, Clinical Features, and Outcomes. *Mycopathologia* 2016; 181: 485–95.
 12. Xiao Z, Wang Q, Zhu F, et al. Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: A retrospective study from 2011 to 2017 in a teaching hospital in China. *Antimicrob Resist Infect Control* 2019; 8: 1–7.
 13. Salehi M, Ghomi Z, Mirshahi R, et al. Epidemiology and outcomes of candidemia in a referral center in Tehran. *Casp J Intern Med* 2019; 10: 73–9.
 14. Sun M, Chen C, Xiao W, et al. Increase in *Candida parapsilosis* candidemia in cancer patients. *Mediterr J Hematol Infect Dis* 2019; 11: 1–7.
 15. Kimura M, Asano-Mori Y, Sakoh T, et al. Factors Associated with Breakthrough Fungemia Caused by *Candida*, *Trichosporon*, or *Fusarium* Species in Patients with Hematological Disorders. *Antimicrob Agents Chemother*; 66. Epub ahead of print 2022. DOI: 10.1128/aac.02081-21
 16. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2015; 62: e1–e50.
 17. Revie NM, Iyer KR, Robbins N, et al. Antifungal drug resistance: evolution, mechanisms and impact. *Curr Opin Microbiol* 2018; 45: 70–6.
 18. Ding X, Yan D, Sun W, et al. Epidemiology and risk factors for nosocomial Non-*Candida albicans* candidemia in adult patients at a tertiary care hospital in North China. *Med Mycol* 2015; 53: 684–90.
 19. Yamin D, Husin A, Harun A. Distribution of candidemia in malaysian tertiary care hospital revealed predominance of *Candida parapsilosis*. *Trop Biomed* 2020; 37: 903–910.
 20. Lima R, Ribeiro FC, Colombo AL, et al. The emerging threat antifungal-resistant *Candida tropicalis* in humans, animals, and environment. *Front Fungal Biol* 2022; 3: 1–11.
 21. Mohanraj H, Vinodhini VM, Vajravelu LK. Mycological Profile of *Candida tropicalis* and its Virulence Factors from Candidemia Patients at A Tertiary Care Facility. *J Pure Appl Microbiol* 2023; 17: 982–92.
 22. Taei M, Chadeganipour M, Mohammadi R. An alarming rise of non - *albicans Candida* species and

- uncommon yeasts in the clinical samples ; a combination of various molecular techniques for identification of etiologic agents. *BMC Res Notes* 2019; 1–7.
23. Bilal H, Shafiq M, Hou B, et al. Distribution and antifungal susceptibility pattern of *Candida* species from mainland China : A systematic analysis Distribution and antifungal susceptibility pattern of *Candida* species from mainland China : A systematic analysis. *Virulence* 2022; 13: 1573–89.
 24. Carolus H, Pierson S, Lagrou K, et al. Amphotericin b and other polyenes—discovery, clinical use, mode of action and drug resistance. *J Fungi* 2020; 6: 1–20.
 25. Maji A, Soutar CP, Zhang J, et al. Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal. *Nature* 2023; 623: 1079–85.
 26. Costa-de-oliveira S, Rodrigues AG. *Candida albicans* antifungal resistance and tolerance in bloodstream infections: The triad yeast-host-antifungal. *Microorganisms*; 8. Epub ahead of print 2020. DOI: 10.3390/microorganisms8020154.
 27. Logan A, Wolfe A, Williamson JC. Antifungal Resistance and the Role of New Therapeutic Agents. *Curr Infect Dis Rep* 2022; 24: 105–16.
 28. Nishimoto AT, Sharma C, Rogers PD. Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus *Candida albicans*. *J Antimicrob Chemother* 2020; 75: 257–70.
 29. Yamin D, Akanmu MH, Al Mutair A, et al. Global Prevalence of Antifungal-Resistant *Candida* parapsilosis: A Systematic Review and Meta-Analysis. *Trop Med Infect Dis*; 7. Epub ahead of print 2022. DOI: 10.3390/tropicalmed7080188.
 30. Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: Summary of the updated recommendations from the European Conference on Infections in Leukaemia. *J Antimicrob Chemother* 2018; 73: 3221–30.
 31. Hossain CM, Ryan LK, Gera M, et al. Antifungals and Drug Resistance. *Encyclopedia* 2022; 2: 1722–37.